Virtus Advisers LLC Acquires 22,878 Shares of Arcutis Biotherapeutics, Inc. $ARQT

Virtus Advisers LLC acquired a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 22,878 shares of the company’s stock, valued at approximately $605,000.

A number of other hedge funds have also recently bought and sold shares of the company. Pinnacle Wealth Planning Services Inc. acquired a new stake in shares of Arcutis Biotherapeutics in the 3rd quarter valued at $36,000. Allworth Financial LP lifted its stake in shares of Arcutis Biotherapeutics by 158.2% during the third quarter. Allworth Financial LP now owns 2,089 shares of the company’s stock valued at $55,000 after acquiring an additional 1,280 shares during the period. Nykredit A S acquired a new position in shares of Arcutis Biotherapeutics during the second quarter valued at $63,000. Integrated Wealth Concepts LLC acquired a new position in shares of Arcutis Biotherapeutics during the second quarter valued at $84,000. Finally, Sterling Capital Management LLC boosted its holdings in Arcutis Biotherapeutics by 839.3% in the third quarter. Sterling Capital Management LLC now owns 3,776 shares of the company’s stock valued at $100,000 after acquiring an additional 3,374 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Morgan Stanley lifted their price objective on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Weiss Ratings raised Arcutis Biotherapeutics from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 29th. Guggenheim upped their target price on shares of Arcutis Biotherapeutics from $38.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, October 19th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $39.00 target price on shares of Arcutis Biotherapeutics in a research note on Thursday, October 8th. Finally, TD Cowen raised their target price on shares of Arcutis Biotherapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Eight analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $39.75.

Read Our Latest Stock Report on Arcutis Biotherapeutics

Insider Buying and Selling at Arcutis Biotherapeutics

In related news, insider Todd Watanabe sold 4,377 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $31.86, for a total value of $139,451.22. Following the completion of the sale, the insider owned 712,826 shares in the company, valued at approximately $22,710,636.36. This represents a 0.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Howard Welgus sold 4,728 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $26.93, for a total value of $127,325.04. Following the completion of the sale, the director owned 35,207 shares of the company’s stock, valued at $948,124.51. This represents a 11.84% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 104,202 shares of company stock valued at $3,034,393 over the last quarter. 9.40% of the stock is owned by corporate insiders.

Arcutis Biotherapeutics Price Performance

ARQT opened at $28.26 on Monday. The company has a fifty day moving average price of $27.54 and a two-hundred day moving average price of $25.40. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.66 and a current ratio of 2.92. Arcutis Biotherapeutics, Inc. has a 52 week low of $19.30 and a 52 week high of $34.80. The firm has a market capitalization of $3.57 billion, a PE ratio of 134.58 and a beta of 1.66.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.12). Arcutis Biotherapeutics had a net margin of 5.88% and a return on equity of 14.18%. The business had revenue of $143.92 million for the quarter, compared to the consensus estimate of $142.59 million. As a group, analysts anticipate that Arcutis Biotherapeutics, Inc. will post 0.28 earnings per share for the current year.

About Arcutis Biotherapeutics

(Free Report)

Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin diseases. Founded in 2016, the company is headquartered in Westlake Village, California. Arcutis primarily serves the U.S. market and continues to develop medicines for dermatologic conditions. Its leadership is headed by President and Chief Executive Officer Frank Watanabe.

Further Reading

Want to see what other hedge funds are holding ARQT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report).

Institutional Ownership by Quarter for Arcutis Biotherapeutics (NASDAQ:ARQT)

Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.